Patients Over 80 Still Benefit From Treatment for AML Blood Cancer
TUESDAY, May 14, 2024 (HealthDay News) — Seniors over 80 with acute myeloid leukemia can safely and effectively take the standard targeted therapy for the blood cancer, a new study finds. The oral drug venetoclax is typically given to older AML patients whose bodies can’t handle the rigors of chemotherapy.Continue Reading